

## C-CAMP to accelerate projects for AMR

03 September 2018 | News

**C-CAMP will provide business, technical and ancillary support to CARB-X funded projects as well potential grantees.**



The Centre for Cellular and Molecular Platforms (C-CAMP), a Department of Biotechnology initiative, has been selected as an Accelerator for projects funded by CARB-X. As part of this partnership, C-CAMP will provide business, technical and ancillary support to CARB-X funded projects as well potential grantees.

CARB-X is the world's largest public-private partnership devoted to early development anti-bacterial R&D. CARB-X is currently funding 33 companies around the world and has a rapidly growing early development portfolio of antibiotics, diagnostics, vaccines and other life-saving products to address drug resistance.

Antimicrobial resistance is a public health challenge that needs a thriving pipeline of new drugs, vaccines and diagnostics to effectively address this growing threat. C-CAMP through the CARB-X Accelerator program will play a crucial role in supporting the CARB-X funded programs.